Worldwide cost of dementia now $604 billion - or 1% of global GDP - and growing

22 September 2010

A landmark report on the global economic impact of dementia finds that Alzheimer's disease and other dementias are exacting a massive toll on the global economy, with the problem set to accelerate in coming years. The worldwide costs of dementia will exceed 1% of global Gross Domestic Product (GDP) in 2010, at $604 billion, and increase to $1,000 billion a year by 2030. Action is needed from governments around the world, the report urges.

The World Alzheimer Report 2010 - issued on World Alzheimer's Day by Alzheimer's Disease International (ADI) - provides the most current and comprehensive global picture of the economic and social costs of the illness. The Report was jointly authored by Anders Wimo of the Karolinska Institutet, Stockholm, Sweden; and Martin Prince, Institute of Psychiatry, King's College London, UK.

Most significant health crisis of 21st Century

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical